Core Viewpoint - The company, Si Rui Pu Microelectronics Technology (Suzhou) Co., Ltd., is issuing convertible bonds and paying cash to acquire 100% equity of Shenzhen Chuangxin Microelectronics Co., Ltd., while also raising matching funds through a private placement of shares [1][2]. Group 1: Stock Issuance Details - The company is issuing 3,047,535 shares to specific investors, which will be listed for trading on February 5, 2026 [2][6]. - After the issuance, the total number of shares will increase from 132,601,444 to 135,648,979 [2][3]. - The newly issued shares represent 2.21% of the company's total share capital [3][4]. Group 2: Lock-up Period and Commitments - The shares issued will have a lock-up period of six months from the date of issuance [3][5]. - There are six shareholders involved in this issuance, all of whom have committed to not transferring their shares during the lock-up period [5][6]. Group 3: Capital Changes and Compliance - As of December 31, 2025, a total of 2,249,360 shares have been converted from the convertible bonds, increasing the total share capital to 137,898,339 [4]. - The independent financial advisor, Huatai United Securities Co., Ltd., confirmed that the share issuance complies with relevant regulations and that the company has accurately disclosed information regarding the share lock-up [5][6].

Group 1 - The core announcement from the company is regarding the release of 3,047,535 restricted shares, which will be available for trading after a 6-month lock-up period [1] - The restricted shares will become tradable on February 5, 2026 [1] Group 2 - The industry is witnessing significant advancements in battery technology, particularly with the introduction of semi-solid state batteries, which are expected to be featured in multiple new vehicle models this year [1] - Major manufacturers are preparing for a competitive year in the power battery sector, indicating a potential shift in technology and market dynamics [1]

华泰联合证券有限责任公司关于思瑞浦微电子科技（苏州）股份 有限公司发行可转换公司债券及支付现金购买资产并募集配套资 金之限售股上市流通的核查意见 华泰联合证券有限责任公司（以下简称"独立财务顾问""华泰联合证券"）作为 思瑞浦微电子科技（苏州）股份有限公司（以下简称"思瑞浦"、"公司"或"上市公 司"）发行可转换公司债券及支付现金购买资产并募集配套资金项目的独立财务顾问， 根据《上市公司重大资产重组管理办法》《上市公司并购重组财务顾问业务管理办法》 等有关法律、法规和规范性文件的规定，对思瑞浦发行可转换公司债券及支付现金购买 资产并募集配套资金相关限售股（以下简称"本次限售股"） 上市流通情况进行了核 查，具体情况如下： 一、本次限售股上市类型 思瑞浦本次限售股上市流通类型为发行可转换公司债券及支付现金购买资产并募 集配套资金之募集配套资金部分限售股，具体如下： （一） 发行可转换公司债券及支付现金购买资产并募集配套资金股份注册情况 2024 年 9 月 11 日，中国证券监督管理委员会出具了《关于同意思瑞浦微电子科技 （苏州）股份有限公司发行可转换公司债券购买资产并募集配套资金注册的批复》（证 监许可〔20 ...

| 证券代码：688536 | 证券简称：思瑞浦 | 公告编号：2026-004 | | --- | --- | --- | | 转债代码：118500 | 转债简称：思瑞定转 | | 思瑞浦微电子科技（苏州）股份有限公司 发行可转换公司债券及支付现金购买资产 并募集配套资金向特定对象发行股票上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 思瑞浦微电子科技（苏州）股份有限公司（以下简称"公司"或"上市公司"） 以发行可转换公司债券及支付现金的方式购买深圳市创芯微微电子有限公司 100%股权并募集配套资金。中国证券监督管理委员会出具《关于同意思瑞浦微电 子科技（苏州）股份有限公司发行可转换公司债券购买资产并募集配套资金注册 的批复》（证监许可〔2024〕1287 号），同意公司发行可转换公司债券及支付现 金购买资产并向特定对象发行股票募集配套资金。公司本次向特定对象发行 A 股 股票 3,047,535 股，本次发行完成后，公司股份总数从普通股 132,601,444 股增加 至普通股 135, ...

Group 1 - The core viewpoint of the news is the strong performance of the semiconductor sector, particularly the "full-chip" ETF launched by Huabao, which has seen significant price increases in its initial days of trading [1][3] - The Huabao ETF, which tracks the Shanghai Stock Exchange's semiconductor index, includes 50 stocks related to semiconductor materials, equipment, design, manufacturing, and testing, with over 90% of its weight in core areas like integrated circuits and semiconductor equipment [3][6] - The index has shown a remarkable annualized return of 17.93% since its inception, outperforming other semiconductor indices, with a lower maximum drawdown, indicating a better risk-return profile [5][6] Group 2 - The semiconductor sector is experiencing a resurgence, driven by strong demand for analog chips and microcontrollers, particularly due to the ongoing construction of AI data centers [3] - Notable stocks within the ETF, such as Yandong Microelectronics, Naxin Micro, and SIRUI, have shown significant price increases, with Yandong Micro leading with a rise of over 10% [1][3] - A recent development from Peking University involves a new chip based on resistive random-access memory (RRAM), which reportedly enhances computing speed by approximately 12 times and energy efficiency by over 228 times compared to current advanced digital chips [2]

Group 1 - The core viewpoint of the news is the strong performance of the Sci-Tech Innovation Chip ETF (华宝, 589190), which saw a price increase of 2.72% on its first day and continued to rise by over 1.5% on the second day, indicating a bullish trend in the semiconductor sector [1][7]. - The ETF includes 50 stocks related to semiconductor materials, equipment, design, manufacturing, packaging, and testing, with over 90% of its weight in core areas like integrated circuits and semiconductor equipment, showcasing a comprehensive layout in the chip industry [3][10]. - The index tracked by the ETF has shown significant annualized returns of 17.93% since its inception, outperforming similar indices and demonstrating a better risk-reward ratio [12][13]. Group 2 - Key stocks within the ETF, such as 燕东微, 纳芯微, and 艾为电子, have shown strong gains, with 燕东微 leading with an increase of over 10% [1][7]. - Recent advancements in chip technology, such as a new chip developed by Peking University's AI Institute, have demonstrated a 12-fold increase in computing speed and over 228 times improvement in energy efficiency compared to current digital chips, indicating ongoing innovation in the sector [10][12]. - Positive signals from major overseas semiconductor companies, like Texas Instruments, indicate a strong recovery in demand for analog chips and microcontrollers, driven by the booming AI data center construction [3][10].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 经思瑞浦微电子科技（苏州）股份有限公司（以下简称"公司"）初步测算： 2025年，公司业务在汽车、AI服务器、光模块、新能源（光伏逆变、储能等）、电源模块、电网、工 控、测试测量、家用电器等市场持续成长，且通过与并购标的深圳市创芯微微电子有限公司的业务融 合，公司实现了在工业、汽车、通信、消费电子四大市场的全面布局，竞争力进一步加强，公司整体出 货量和营收实现大幅增长。同时，得益于加强经营管理及成本费用的管控，公司整体效益显著提升，相 关费用并未随营业收入的增加而大幅增加。 四、风险提示 本次业绩预告是公司财务部门的初步核算，尚未经注册会计师审计。公司尚未发现影响本次业绩预告内 容准确性的重大不确定因素。 1、经财务部门初步测算，预计2025年年度实现营业收入213,000万元至215,000万元，较上年同期相比， 将增加91,046万元至93,046万元，同比增长74.6 ...

证券代码：688536 证券简称：思瑞浦 公告编号：2026-003 1、经财务部门初步测算，预计2025年年度实现营业收入213,000万元至215,000万元，较上年同期相比， 将增加91,046万元至93,046万元，同比增长74.66%至76.30%。 2、预计2025年年度实现归属于上市公司所有者的净利润为16,500万元到18,400万元，较上年同期相比， 将增加36,222万元至38,122万元，实现扭亏为盈。 转债代码：118500 转债简称：思瑞定转 思瑞浦微电子科技（苏州）股份有限公司 2025年年度业绩预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 经思瑞浦微电子科技（苏州）股份有限公司（以下简称"公司"）初步测算： 3、预计2025年年度实现归属于上市公司所有者扣除非经常性损益后的净利润为10,500万元到12,600万 元，较上年同期相比，将增加38,604万元至40,704万元。 4 ...

Group 1 - ShenNan Electric A expects a net profit increase of 584.66%-721.59% year-on-year for 2025 [1] - Te Yi Pharmaceutical anticipates a net profit increase of 241.55%-339.13% year-on-year for 2025 [1] - RunTu Co. forecasts a net profit increase of 181.05%-227.89% year-on-year for 2025 [1] - QingSong Co. projects a net profit increase of 137.73%-201.74% year-on-year for 2025 [1] - RuiSheng Intelligent expects a net profit increase of 112.00%-139.99% year-on-year for 2025 [1] - JianKai Technology anticipates a net profit increase of 101.09%-121.20% year-on-year for 2025 [1] - XingQi Eye Medicine forecasts a net profit increase of 95.82%-121.56% year-on-year for 2025 [1] - RuiChuang MicroNano expects a net profit increase of approximately 93% year-on-year for 2025 [1] - TianHe Co. projects a net profit increase of 84.35%-169.78% year-on-year for 2025 [1] - ZhongYuan Co. anticipates a net profit increase of 80%-105% year-on-year for 2025 [1] - YiDao Information expects a net profit increase of 76.04%-128.85% year-on-year for 2025 [1] - ShengDa Bio forecasts a net profit increase of 69.93%-120.90% year-on-year for 2025 [1] - HuaRui Precision anticipates a net profit increase of 68.29%-86.99% year-on-year for 2025 [1] - FangZheng Technology expects a net profit increase of 67.06%-98.14% year-on-year for 2025 [1] - JinLing Hotel projects a net profit increase of 65.37%-90.93% year-on-year for 2025 [1] - QiangYi Co. anticipates a net profit increase of 57.87%-71.17% year-on-year for 2025 [1] - LangBo Technology expects a net profit increase of 57.58%-66.53% year-on-year for 2025 [1] - HuaFeng Measurement and Control forecasts a net profit increase of 46%-78% year-on-year for 2025 [1] - Zhaoyi Innovation anticipates a net profit increase of approximately 46% year-on-year for 2025 [1] - JieChang Drive expects a net profit increase of 40%-55% year-on-year for 2025 [1] - ShengYuan Environmental Protection projects a net profit increase of 31.79%-59.24% year-on-year for 2025 [1] - GuangHa Communication anticipates a net profit increase of 21.83%-31.31% year-on-year for 2025 [1] - MaiHe Co. expects a net profit increase of 19.58%-54.76% year-on-year for 2025 [1] Group 2 - YiLing Pharmaceutical expects a net profit of 1.2 billion to 1.3 billion yuan for 2025, turning profitable year-on-year [1] - LiYade anticipates a net profit of 300 million to 380 million yuan for 2025, turning profitable year-on-year [1] - SiRuiPu expects a net profit of 165 million to 184 million yuan for 2025, turning profitable year-on-year [1] - DaMing City anticipates a net profit of 140 million to 165 million yuan for 2025, turning profitable year-on-year [1] - DaHeng Technology expects a net profit of 106 million yuan for 2025, turning profitable year-on-year [1] - GuangHua Technology projects a net profit of 85 million to 120 million yuan for 2025, turning profitable year-on-year [1] - BoTeng Co. expects a net profit of 80 million to 105 million yuan for 2025, turning profitable year-on-year [2] - ZhongBing HongJian anticipates a net profit of 34 million to 46 million yuan for 2025, turning profitable year-on-year [2]

Major Announcements - Zhaoyi Innovation plans to use 500 million CNY of A-share fundraising to increase capital in its wholly-owned subsidiaries for the implementation of the DRAM project [1] - Haiguang Information's mid-2025 profit distribution plan includes a cash dividend of 0.09 CNY per share, totaling 209 million CNY [2] - *ST Biology has terminated the major asset restructuring plan to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. [3] - Fosun Pharma intends to spin off its subsidiary Fosun Antigen for independent listing on the Hong Kong Stock Exchange [4] - Jingchen Co. has set the inquiry transfer price at 82.85 CNY per share for the transfer of 13.1 million shares [5] Performance Forecasts - Zhaoyi Innovation expects a net profit of approximately 1.61 billion CNY for 2025, a year-on-year increase of about 46% [9] - Longying Precision anticipates a net profit decrease of 17.70% to 29.36% for 2025, estimating between 545 million CNY and 635 million CNY [9] - Ruichuang Micro-Nano forecasts a net profit of around 1.1 billion CNY for 2025, representing a 93% increase [10] - Nanjing Bank projects a net profit of 21.81 billion CNY for 2025, an 8.08% increase year-on-year [11] - Zhongyuan Co. expects a net profit increase of 80% to 105% for 2025, estimating between 139 million CNY and 158 million CNY [12] - Qiangyi Co. anticipates a net profit increase of 57.87% to 71.17% for 2025, estimating between 368 million CNY and 399 million CNY [13] - Liard expects a net profit of 300 million CNY to 380 million CNY for 2025, turning from a loss of 889 million CNY in the previous year [14] - Daheng Technology forecasts a net profit of approximately 106 million CNY for 2025, also turning from a loss [16] - Dongfeng Co. anticipates a net loss of 390 million CNY to 480 million CNY for 2025 [17] - Qing Song Co. expects a net profit increase of 137.73% to 201.74% for 2025, estimating between 130 million CNY and 165 million CNY [18] - SIRUI Co. forecasts a net profit of 165 million CNY to 184 million CNY for 2025, turning from a loss [19] - Shengmei Shanghai expects a revenue increase of 18.91% to 22.47% for 2025, estimating between 6.68 billion CNY and 6.88 billion CNY [20] - Yijun Co. anticipates a net loss of 11 million CNY to 14 million CNY for 2025 [21] - Saint Yuan Environmental Protection expects a net profit increase of 31.79% to 59.24% for 2025, estimating between 240 million CNY and 290 million CNY [22] - Lijun Co. forecasts a net profit decrease of 45.05% to 60.03% for 2025, estimating between 4.8 million CNY and 6.6 million CNY [23] - Xingqi Eye Medicine expects a net profit increase of 95.82% to 121.56% for 2025, estimating between 662 million CNY and 749 million CNY [25] - Beidou Star expects a net loss of 230 million CNY to 290 million CNY for 2025, reducing losses compared to the previous year [26] - Yiling Pharmaceutical anticipates a net profit of 1.2 billion CNY to 1.3 billion CNY for 2025, turning from a loss of 725 million CNY [27] - Zhijiang Bio forecasts a net loss of 32 million CNY to 47 million CNY for 2025, reducing losses compared to the previous year [28] - Yema Battery expects a net profit decrease of 58% to 70% for 2025, estimating between 45.83 million CNY and 64.17 million CNY [29] - Yunmei Energy anticipates a net loss of 410 million CNY to 470 million CNY for 2025 [30] - Yingfang Micro expects a net loss of 69 million CNY to 97 million CNY for 2025 [31] - Guanghua Technology forecasts a net profit of 85 million CNY to 120 million CNY for 2025, turning from a loss [33] Share Buybacks - Hengyi Petrochemical plans to repurchase shares worth 500 million CNY to 1 billion CNY [34] - Yunyi Electric plans to repurchase shares worth 100 million CNY to 150 million CNY [34] - Xidun Pharmaceutical plans to repurchase shares worth 25 million CNY to 50 million CNY [35]